Department of Cardiovascular Medicine, Osaka, Japan.
Biochem Biophys Res Commun. 2010 Feb 26;393(1):55-60. doi: 10.1016/j.bbrc.2010.01.076. Epub 2010 Jan 25.
Although various management methods have been developed for heart failure, it is necessary to investigate the diagnostic or therapeutic targets of heart failure. Accordingly, we have developed different approaches for managing heart failure by using conventional microarray analyses. We analyzed gene expression profiles of myocardial samples from 12 patients with heart failure and constructed datasets of heart failure-associated genes using clinical parameters such as pulmonary artery pressure (PAP) and ejection fraction (EF). From these 12 genes, we selected four genes with high expression levels in the heart, and examined their novelty by performing a literature-based search. In addition, we included four G-protein-coupled receptor (GPCR)-encoding genes, three enzyme-encoding genes, and one ion-channel protein-encoding gene to identify a drug target for heart failure using in silico microarray database. After the in vitro functional screening using adenovirus transfections of 12 genes into rat cardiomyocytes, we generated gene-targeting mice of five candidate genes, namely, MYLK3, GPR37L1, GPR35, MMP23, and NBC1. The results revealed that systolic blood pressure differed significantly between GPR35-KO and GPR35-WT mice as well as between GPR37L1-Tg and GPR37L1-KO mice. Further, the heart weight/body weight ratio between MYLK3-Tg and MYLK3-WT mice and between GPR37L1-Tg and GPR37L1-KO mice differed significantly. Hence, microarray analysis combined with clinical parameters can be an effective method to identify novel therapeutic targets for the prevention or management of heart failure.
尽管已经开发出各种心力衰竭的管理方法,但仍有必要研究心力衰竭的诊断或治疗靶点。因此,我们使用常规微阵列分析开发了不同的心力衰竭管理方法。我们分析了 12 例心力衰竭患者心肌样本的基因表达谱,并使用肺动脉压 (PAP) 和射血分数 (EF) 等临床参数构建了心力衰竭相关基因数据集。从这 12 个基因中,我们选择了在心脏中高表达的四个基因,并通过文献检索来检查它们的新颖性。此外,我们还包括四个 G 蛋白偶联受体 (GPCR) 编码基因、三个酶编码基因和一个离子通道蛋白编码基因,使用基于计算的微阵列数据库来鉴定心力衰竭的药物靶点。在通过腺病毒转染将 12 个基因转入大鼠心肌细胞进行体外功能筛选后,我们生成了五个候选基因(即 MYLK3、GPR37L1、GPR35、MMP23 和 NBC1)的基因靶向小鼠。结果表明,GPR35-KO 和 GPR35-WT 小鼠以及 GPR37L1-Tg 和 GPR37L1-KO 小鼠之间的收缩压差异显著。此外,MYLK3-Tg 和 MYLK3-WT 小鼠以及 GPR37L1-Tg 和 GPR37L1-KO 小鼠之间的心脏重量/体重比差异显著。因此,微阵列分析结合临床参数可以是一种有效的方法,用于识别预防或管理心力衰竭的新的治疗靶点。